<code id='AD66267B6A'></code><style id='AD66267B6A'></style>
    • <acronym id='AD66267B6A'></acronym>
      <center id='AD66267B6A'><center id='AD66267B6A'><tfoot id='AD66267B6A'></tfoot></center><abbr id='AD66267B6A'><dir id='AD66267B6A'><tfoot id='AD66267B6A'></tfoot><noframes id='AD66267B6A'>

    • <optgroup id='AD66267B6A'><strike id='AD66267B6A'><sup id='AD66267B6A'></sup></strike><code id='AD66267B6A'></code></optgroup>
        1. <b id='AD66267B6A'><label id='AD66267B6A'><select id='AD66267B6A'><dt id='AD66267B6A'><span id='AD66267B6A'></span></dt></select></label></b><u id='AD66267B6A'></u>
          <i id='AD66267B6A'><strike id='AD66267B6A'><tt id='AD66267B6A'><pre id='AD66267B6A'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:23621
          Sammy Kimball for STAT

          Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.

          advertisement

          For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          In utero gene editing: an explainer
          In utero gene editing: an explainer

          AnnaYeo/STATRecentlyapprovedgenetherapiesofferpatientsone-time,potentiallycurativetreatmentsforgenet

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          6 phony surgeries that take placebo to the extreme

          AFP/GettyImagesMostofthetime,it’seasytobeintheplacebogroup ofaclinicaltrial:nosideeffects,minimalann